The Odd Faces of Oligomers: The Case of TRAF2-C, A Trimeric C-Terminal Domain of TNF Receptor-Associated Factor.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 May 2021
Historique:
received: 26 04 2021
revised: 20 05 2021
accepted: 26 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 24 6 2021
Statut: epublish

Résumé

TNF Receptor Associated Factor 2 (TRAF2) is a trimeric protein that belongs to the TNF receptor associated factor family (TRAFs). The TRAF2 oligomeric state is crucial for receptor binding and for its interaction with other proteins involved in the TNFR signaling. The monomer-trimer equilibrium of a C- terminal domain truncated form of TRAF2 (TRAF2-C), plays also a relevant role in binding the membrane, causing inward vesiculation. In this study, we have investigated the conformational dynamics of TRAF2-C through circular dichroism, fluorescence, and dynamic light scattering, performing temperature-dependent measurements. The data indicate that the protein retains its oligomeric state and most of its secondary structure, while displaying a significative increase in the heterogeneity of the tyrosines signal, increasing the temperature from ≈15 to ≈35 °C. The peculiar crowding of tyrosine residues (12 out of 18) at the three subunit interfaces and the strong dependence on the trimer concentration indicate that such conformational changes mainly involve the contact areas between each pair of monomers, affecting the oligomeric state. Molecular dynamic simulations in this temperature range suggest that the interfaces heterogeneity is an intrinsic property of the trimer that arises from the continuous, asymmetric approaching and distancing of its subunits. Such dynamics affect the results of molecular docking on the external protein surface using receptor peptides, indicating that the TRAF2-receptor interaction in the solution might not involve three subunits at the same time, as suggested by the static analysis obtainable from the crystal structure. These findings shed new light on the role that the TRAF2 oligomeric state might have in regulating the protein binding activity in vivo.

Identifiants

pubmed: 34070875
pii: ijms22115871
doi: 10.3390/ijms22115871
pmc: PMC8198530
pii:
doi:

Substances chimiques

AGFG1 protein, human 0
Inhibitor of Apoptosis Proteins 0
Nuclear Pore Complex Proteins 0
Protein Isoforms 0
Protein Subunits 0
RNA-Binding Proteins 0
Recombinant Proteins 0
TNF Receptor-Associated Death Domain Protein 0
TNF Receptor-Associated Factor 2 0
Tyrosine 42HK56048U
TRAIP protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
Proprotein Convertases EC 3.4.21.-
Serine Endopeptidases EC 3.4.21.-
membrane-bound transcription factor peptidase, site 1 EC 3.4.21.112

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Università degli Studi di Roma Tor Vergata
ID : E84I20000560005

Références

Sci Rep. 2017 Jun 6;7(1):2838
pubmed: 28588190
Biol Direct. 2020 Nov 2;15(1):21
pubmed: 33138856
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):813-822
pubmed: 28499815
Science. 2015 Dec 11;350(6266):aaa2245
pubmed: 26659058
Mol Cell. 1999 Sep;4(3):321-30
pubmed: 10518213
Front Immunol. 2018 Aug 09;9:1849
pubmed: 30140268
Br J Pharmacol. 2015 Dec;172(23):5523-30
pubmed: 25651870
Cell Death Differ. 2010 Jan;17(1):35-45
pubmed: 19680262
Bioinformatics. 2011 Oct 15;27(20):2915-6
pubmed: 21873642
Cell Death Dis. 2014 Jan 23;5:e1015
pubmed: 24457959
J Biol Chem. 1999 Apr 30;274(18):12193-6
pubmed: 10212181
J Mol Biol. 2007 Feb 2;365(5):1596-606
pubmed: 17141268
Chem Rev. 2013 Mar 13;113(3):1598-613
pubmed: 23186336
Biol Direct. 2020 Oct 16;15(1):19
pubmed: 33066821
Annu Rev Biochem. 2001;70:149-80
pubmed: 11395405
Methods Mol Biol. 2021;2253:1-6
pubmed: 33315214
Mol Cell. 2010 Apr 9;38(1):101-13
pubmed: 20385093
Arch Biochem Biophys. 2013 Mar;531(1-2):44-64
pubmed: 23246784
Biophys J. 2005 Dec;89(6):4159-70
pubmed: 16150969
J Am Chem Soc. 2019 Jul 24;141(29):11540-11556
pubmed: 31188575
ACS Omega. 2019 Jan 10;4(1):911-919
pubmed: 31459367
Biol Direct. 2020 Sep 16;15(1):12
pubmed: 32938494
Biochem Soc Trans. 2012 Jun 1;40(3):475-91
pubmed: 22616857
Bioinformatics. 2009 Nov 1;25(21):2843-4
pubmed: 19759195
Methods Mol Biol. 2021;2253:7-20
pubmed: 33315215
Biochim Biophys Acta. 2009 Feb;1793(2):346-53
pubmed: 18952128
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Biotechnol Appl Biochem. 2018 Jan;65(1):38-45
pubmed: 28960521
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Science. 2002 May 31;296(5573):1634-5
pubmed: 12040173
Cell. 2000 Jun 23;101(7):777-87
pubmed: 10892748
Front Cell Dev Biol. 2020 May 21;8:365
pubmed: 32671059
Biochemistry. 2015 Oct 13;54(40):6153-61
pubmed: 26390021
J Biomol Struct Dyn. 2021 Jan;39(1):319-329
pubmed: 31980009
ISRN Oncol. 2013 Jun 11;2013:371854
pubmed: 23840967
Bioinformation. 2017 Jun 30;13(6):164-173
pubmed: 28729757
Prog Mol Biol Transl Sci. 2013;117:25-51
pubmed: 23663964
J Phys Chem Lett. 2020 Sep 3;11(17):7021-7027
pubmed: 32787330
PLoS Comput Biol. 2006 Nov 17;2(11):e155
pubmed: 17112313
Med Microbiol Immunol. 2020 Jun;209(3):233-242
pubmed: 31865405
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8408-13
pubmed: 10411888
Front Cell Dev Biol. 2021 Feb 11;8:615141
pubmed: 33644033
Nature. 1999 Apr 8;398(6727):533-8
pubmed: 10206649
Protein J. 2008 Jan;27(1):59-70
pubmed: 17851740
Biol Direct. 2019 Jan 15;14(1):1
pubmed: 30646935
J Proteome Res. 2020 Nov 6;19(11):4576-4586
pubmed: 32551648
FEBS J. 2005 Jan;272(1):16-27
pubmed: 15634328
Prog Biophys Mol Biol. 2008 Sep;98(1):61-84
pubmed: 18602415

Auteurs

Almerinda Di Venere (A)

Department of Experimental Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133 Rome, Italy.

Eleonora Nicolai (E)

Department of Experimental Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133 Rome, Italy.

Velia Minicozzi (V)

Department of Physics, Tor Vergata University of Rome, Via Della Ricerca Scientifica 1, 00133 Rome, Italy.

Anna Maria Caccuri (AM)

Department of Chemistry, University of Rome Tor Vergata, Via Della Ricerca Scientifica 1, 00133 Rome, Italy.

Luisa Di Paola (L)

Unit of Chemical-Physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy.

Giampiero Mei (G)

Department of Experimental Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH